Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fortrea Holdings Inc. - Common Stock (NQ:FTRE)

9.640 -0.340 (-3.41%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Fortrea Holdings Inc. - Common Stock

< Previous 1 2 3 4 Next >
Why Is Inflammation Disease Focused Acelyrin Stock Trading Lower Today?
Acelyrin Inc (NASDAQ: SLRN) updated its izokibep clinical development program, including its ongoing global Phase 2b/3 trial for izokibep in  
Via Benzinga
Fortrea Announces AI-Driven Partnership with Medidata to Increase Diversity in Clinical Trials
Collaboration leverages Medidata AI to improve access and participation of diverse population groups in clinical studies 
From Fortrea Holdings Inc
Via GlobeNewswire
Why Fortrea Holdings Stock Climbed Nearly 10% Higher Today
The company's first quarter as a separate entity was better than anticipated. 
Via The Motley Fool
Monday.Com Reports Q3 Beat, Joins Fortrea Holdings, Henry Schein And Other Big Stocks Moving Higher On Monday
U.S. stocks traded lower, with the Dow Jones falling around 40 points on Monday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Fortrea Holdings Shares Are Gaining Today
Activist hedge fund Starboard Value holds a  
Via Benzinga
Earnings Scheduled For November 13, 2023
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter. 
Via Benzinga
Fortrea Reports Third Quarter 2023 Results
From Fortrea Holdings Inc
Via GlobeNewswire
Fortrea Completes Expansion of Clinical Pharmacology Solutions Following Targeted Investments at its Four Clinical Research Units in U.S. and U.K.
Adds speed and agility with cGMP production at on-site pharmacies, adds capacity, improves flexible therapeutic capabilities and enhances experience for study volunteers 
From Fortrea Holdings Inc
Via GlobeNewswire
Starboard Value Issues Presentation Delivered at 13D Monitor’s 2023 Active-Passive Investor Summit
From Starboard Value LP
Via Business Wire
Fortrea Appoints Life Science Executive Dr. John Doyle to Lead Consulting Team
Industry veteran brings more than three decades of experience spanning R&D, commercialization, and market access 
From Fortrea Holdings Inc
Via GlobeNewswire
Fortrea Announces Date for Third Quarter 2023 Financial Results and Conference Call
From Fortrea Holdings Inc
Via GlobeNewswire
Fortrea’s Jim Cameli Named a Top 100 Global Chief Information Security Officer by HotTopics
From Fortrea Holdings Inc
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2023
Via Benzinga
Fortrea to Present at the Baird 2023 Global Healthcare Conference
From Fortrea Holdings Inc
Via GlobeNewswire
Fortrea to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
From Fortrea Holdings Inc
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 16, 2023
Via Benzinga
Why Fortrea Holdings Stock Is Sinking Today
The contract research organization's first quarterly update as a stand-alone entity disappointed investors. 
Via The Motley Fool
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Fortrea Reports Second Quarter 2023 Results and Provides Full-Year 2023 Guidance
From Fortrea Holdings Inc
Via GlobeNewswire
Why 22nd Century Group Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) shares jumped 283.7% to $1.3007 after Harmony Biosciences entered into definitive agreement to acquire the company for total potential consideration... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 7, 2023
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  On Friday, 73 companies reached new 52-week lows. 
Via Benzinga
Fortrea Announces Date for Second Quarter 2023 Financial Results and Conference Call
From Fortrea Holdings Inc
Via GlobeNewswire
Fortrea To Manage Incannex's FDA IND Opening Phase 2/3 Trial Of Its Dronabinol-Based Drug For Obstructive Sleep Apnea
Incannex Healthcare Limited (NASDAQ: IXHL) (ASX: IHL) has engaged Fortrea (NASDAQ: FTRE) as the contract research organisation for management of the IND opening p 
Via Benzinga
Visualizing The Entire S&P 500
One of the biggest challenges market analysts have is how to visualize the companies that make up the S&P 500. 
Via Talk Markets
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.